MBX Biosciences Drug Shows Mixed Results in Clinical Trial

Boston, MA — MBX Biosciences reported results on Monday from a clinical trial of its experimental drug, canvuparatide, which aims to treat chronic hypoparathyroidism. The drug achieved the primary goal of the mid-stage trial, but the results raised concerns among investors regarding its effectiveness compared to existing treatments.

The 12-week study found a 63% response rate in participants who received canvuparatide, compared to a 31% response rate in the placebo group. While the results were statistically significant, they fell short of expectations. Analysts pointed to a high placebo response rate as a factor that may have narrowed the treatment effect.

Investors are particularly interested in how canvuparatide stacks up against Yorvipath, a competing drug from Ascendis Pharma that won approval last year. The mixed results of the trial may invite skepticism about the market potential for canvuparatide.

No further details about the trial’s methodology or the specific patient demographics have been released at this time. MBX Biosciences is expected to conduct further analyses to understand the implications of the trial findings.